{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:02:06Z","timestamp":1771542126697,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04448-6","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:05:48Z","timestamp":1752141948000},"page":"531-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A bibliometric analysis of the current research status and hotspots regarding Aducanumab treatment for Alzheimer's disease"],"prefix":"10.1007","volume":"399","author":[{"given":"Dingwen","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"4448_CR1","doi-asserted-by":"publisher","first-page":"102129","DOI":"10.1016\/j.arr.2023.102129","volume":"92","author":"A Amrapala","year":"2023","unstructured":"Amrapala A, Sab\u00e9 M, Solmi M, Maes M (2023) Neuropsychiatric disturbances in mild cognitive impairment: A scientometric analysis. Ageing Res Rev 92:102129. https:\/\/doi.org\/10.1016\/j.arr.2023.102129","journal-title":"Ageing Res Rev"},{"key":"4448_CR2","doi-asserted-by":"publisher","unstructured":"Ashvin DR, Kumari S, Sharma P, Vellingiri B, Medhi B et al. (2025) Unraveling the immune puzzle: Role of immunomodulation in Alzheimer's disease. J Neuroimmune Pharmacol 20(1):47. https:\/\/doi.org\/10.1007\/s11481-025-10210-9","DOI":"10.1007\/s11481-025-10210-9"},{"key":"4448_CR3","doi-asserted-by":"publisher","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al. (2022) Two randomized phase 3 studies of Aducanumab in early Alzheimer's Disease. J Prev Alzheimers Dis 9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","DOI":"10.14283\/jpad.2022.30"},{"key":"4448_CR4","doi-asserted-by":"publisher","unstructured":"Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT et al. (2024) Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med 221(2). https:\/\/doi.org\/10.1084\/jem.20231363","DOI":"10.1084\/jem.20231363"},{"key":"4448_CR5","doi-asserted-by":"publisher","unstructured":"Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M (2021) Aducanumab: Appropriate use recommendations. J Prev Alzheimers Dis 8(4): 398\u2013410. https:\/\/doi.org\/10.14283\/jpad.2021.41","DOI":"10.14283\/jpad.2021.41"},{"key":"4448_CR6","doi-asserted-by":"publisher","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S et al. (2022) Aducanumab: Appropriate use recommendations update. J Prev Alzheimers Dis 9(2): 221\u2013230. https:\/\/doi.org\/10.14283\/jpad.2022.34","DOI":"10.14283\/jpad.2022.34"},{"issue":"12","key":"4448_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Aducanumab: First approval. Drugs 81(12):1437\u20131443. https:\/\/doi.org\/10.1007\/s40265-021-01569-z","journal-title":"Drugs"},{"issue":"6","key":"4448_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/s1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S et al (2021) Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol 20(6):484\u2013496. https:\/\/doi.org\/10.1016\/s1474-4422(21)00066-1","journal-title":"Lancet Neurol"},{"issue":"10","key":"4448_CR9","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","volume":"181","author":"B Dunn","year":"2021","unstructured":"Dunn B, Stein P, Cavazzoni P (2021) Approval of Aducanumab for Alzheimer Disease-The FDA\u2019s perspective. JAMA Intern Med 181(10):1276\u20131278. https:\/\/doi.org\/10.1001\/jamainternmed.2021.4607","journal-title":"JAMA Intern Med"},{"issue":"3","key":"4448_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41582-020-00454-9","volume":"17","author":"H Fillit","year":"2021","unstructured":"Fillit H, Green A (2021) Aducanumab and the FDA - where are we now? Nat Rev Neurol 17(3):129\u2013130. https:\/\/doi.org\/10.1038\/s41582-020-00454-9","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"4448_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jalz.2018.03.009","volume":"14","author":"T Iwatsubo","year":"2018","unstructured":"Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K et al (2018) Japanese and North American Alzheimer\u2019s Disease neuroimaging initiative studies: Harmonization for international trials. Alzheimers Dement 14(8):1077\u20131087. https:\/\/doi.org\/10.1016\/j.jalz.2018.03.009","journal-title":"Alzheimers Dement"},{"issue":"20","key":"4448_CR12","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker M, Walker LC (2023) Alzheimer\u2019s disease: From immunotherapy to immunoprevention. Cell 186(20):4260\u20134270. https:\/\/doi.org\/10.1016\/j.cell.2023.08.021","journal-title":"Cell"},{"issue":"1","key":"4448_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/psp4.12728","volume":"11","author":"K Kandadi Muralidharan","year":"2022","unstructured":"Kandadi Muralidharan K, Tong X, Kowalski KG, Rajagovindan R, Lin L, Budd Haberlain S et al (2022) Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer\u2019s disease. CPT Pharmacometrics Syst Pharmacol 11(1):7\u201319. https:\/\/doi.org\/10.1002\/psp4.12728","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"4448_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2174\/1570159x18666200528142429","volume":"18","author":"S Khan","year":"2020","unstructured":"Khan S, Barve KH, Kumar MS (2020) Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer\u2019s Disease. Curr Neuropharmacol 18(11):1106\u20131125. https:\/\/doi.org\/10.2174\/1570159x18666200528142429","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"4448_CR15","doi-asserted-by":"publisher","first-page":"e207919","DOI":"10.1212\/wnl.0000000000207919","volume":"102","author":"SJ Loomis","year":"2024","unstructured":"Loomis SJ, Miller R, Castrillo-Viguera C, Umans K, Cheng W, O\u2019Gorman J et al (2024) Genome-wide association studies of ARIA from the Aducanumab phase 3 ENGAGE and emerge studies. Neurology 102(3):e207919. https:\/\/doi.org\/10.1212\/wnl.0000000000207919","journal-title":"Neurology"},{"key":"4448_CR16","doi-asserted-by":"publisher","unstructured":"Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I et al. (2021) Donanemab (LY3002813) phase 1b study in Alzheimer's disease: Rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging. J Prev Alzheimers Dis 8(4): 414\u2013424. https:\/\/doi.org\/10.14283\/jpad.2021.56","DOI":"10.14283\/jpad.2021.56"},{"key":"4448_CR17","doi-asserted-by":"publisher","unstructured":"Lozupone M, Dibello V, Resta E, Sardone R, Castellana F, Zupo R et al. (2025) Uncertainties in Anti-Amyloid monoclonal antibody therapy for Alzheimer's disease: the challenges ahead. Expert Rev Neurotherhttps:\/\/doi.org\/10.1080\/14737175.2025.2500752","DOI":"10.1080\/14737175.2025.2500752"},{"key":"4448_CR18","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.arr.2024.102193","volume":"94","author":"S Maheshwari","year":"2024","unstructured":"Maheshwari S, Singh A, Ansari VA, Mahmood T, Wasim R, Akhtar J et al (2024) Navigating the dementia landscape: Biomarkers and emerging therapies. Ageing Res Rev 94:102193. https:\/\/doi.org\/10.1016\/j.arr.2024.102193","journal-title":"Ageing Res Rev"},{"issue":"9","key":"4448_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/14737175.2024.2367016","volume":"24","author":"A Menegaz de Almeida","year":"2024","unstructured":"Menegaz de Almeida A, Leite M, Lopes LM, Gomes Lima P, Siegloch Barros ML, Rocha Pinheiro S et al (2024) Gantenerumab for early Alzheimer\u2019s disease: a systematic review and meta-analysis. Expert Rev Neurother 24(9):929\u2013936. https:\/\/doi.org\/10.1080\/14737175.2024.2367016","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"4448_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2023.12.001","volume":"57","author":"A Millet","year":"2024","unstructured":"Millet A, Ledo JH, Tavazoie SF (2024) An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer\u2019s brains. Immunity 57(1):153-170.e156. https:\/\/doi.org\/10.1016\/j.immuni.2023.12.001","journal-title":"Immunity"},{"issue":"18","key":"4448_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW et al (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med 384(18):1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"issue":"3","key":"4448_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/14712598.2025.2463963","volume":"25","author":"F Panza","year":"2025","unstructured":"Panza F, Dibello V, Sardone R, Zupo R, Castellana F, Leccisotti I et al (2025) Successes and failures: the latest advances in the clinical development of amyloid-\u03b2-targeting monoclonal antibodies for treating Alzheimer\u2019s disease. Expert Opin Biol Ther 25(3):275\u2013283. https:\/\/doi.org\/10.1080\/14712598.2025.2463963","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"4448_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1056\/NEJMp2111320","volume":"385","author":"GD Rabinovici","year":"2021","unstructured":"Rabinovici GD (2021) Controversy and progress in Alzheimer\u2019s disease - FDA approval of Aducanumab. N Engl J Med 385(9):771\u2013774. https:\/\/doi.org\/10.1056\/NEJMp2111320","journal-title":"N Engl J Med"},{"key":"4448_CR24","doi-asserted-by":"publisher","unstructured":"Restifo LL, Erickson RP (2023) Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer's disease: A case report. SAGE Open Med Case Rep 11, 2050313x231194507. https:\/\/doi.org\/10.1177\/2050313x231194507","DOI":"10.1177\/2050313x231194507"},{"issue":"6","key":"4448_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/clpt.2013.63","volume":"93","author":"KS Reynolds","year":"2013","unstructured":"Reynolds KS (2013) Acceleration of drug development: a collaboration of many stakeholders. Clin Pharmacol Ther 93(6):455\u2013459. https:\/\/doi.org\/10.1038\/clpt.2013.63","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4448_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMoa2308719","volume":"390","author":"AR Rezai","year":"2024","unstructured":"Rezai AR, D\u2019Haese PF, Finomore V, Carpenter J, Ranjan M, Wilhelmsen K et al (2024) Ultrasound blood-brain barrier opening and Aducanumab in Alzheimer\u2019s disease. N Engl J Med 390(1):55\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2308719","journal-title":"N Engl J Med"},{"key":"4448_CR27","doi-asserted-by":"publisher","first-page":"1474043","DOI":"10.3389\/fmed.2024.1474043","volume":"11","author":"S Safiri","year":"2024","unstructured":"Safiri S, Ghaffari Jolfayi A, Fazlollahi A, Morsali S, Sarkesh A, Daei Sorkhabi A et al (2024) Alzheimer\u2019s disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. Front Med (Lausanne) 11:1474043. https:\/\/doi.org\/10.3389\/fmed.2024.1474043","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4448_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D et al (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating Aducanumab in patients with early Alzheimer disease. JAMA Neurol 79(1):13\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161","journal-title":"JAMA Neurol"},{"issue":"4","key":"4448_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370(4):322\u2013333. https:\/\/doi.org\/10.1056\/NEJMoa1304839","journal-title":"N Engl J Med"},{"issue":"10284","key":"4448_CR30","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE et al (2021) Alzheimer\u2019s disease. Lancet 397(10284):1577\u20131590. https:\/\/doi.org\/10.1016\/s0140-6736(20)32205-4","journal-title":"Lancet"},{"issue":"7618","key":"4448_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M et al (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537(7618):50\u201356. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"key":"4448_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/bmj.p6","volume":"380","author":"JH Tanne","year":"2023","unstructured":"Tanne JH (2023) Aduhelm: Approval of Alzheimer\u2019s drug was highly unorthodox, finds report. BMJ 380:6. https:\/\/doi.org\/10.1136\/bmj.p6","journal-title":"BMJ"},{"issue":"4","key":"4448_CR33","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2022.01.016","volume":"27","author":"SA Tatulian","year":"2022","unstructured":"Tatulian SA (2022) Challenges and hopes for Alzheimer\u2019s disease. Drug Discov Today 27(4):1027\u20131043. https:\/\/doi.org\/10.1016\/j.drudis.2022.01.016","journal-title":"Drug Discov Today"},{"key":"4448_CR34","doi-asserted-by":"publisher","first-page":"102203","DOI":"10.1016\/j.arr.2024.102203","volume":"94","author":"I Terao","year":"2024","unstructured":"Terao I, Kodama W (2024) Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer\u2019s disease: A systematic review and network meta-analysis. Ageing Res Rev 94:102203. https:\/\/doi.org\/10.1016\/j.arr.2024.102203","journal-title":"Ageing Res Rev"},{"key":"4448_CR35","doi-asserted-by":"publisher","unstructured":"Toda Y, Iwatsubo T, Nakamura Y, Matsuda N, Miyata M, Jin M et al. (2024) Japanese subgroup analyses from EMERGE and ENGAGE, phase 3 clinical trials of Aducanumab in patients with early Alzheimer's disease. J Prev Alzheimers Dis 11(5):1260\u20131269. https:\/\/doi.org\/10.14283\/jpad.2024.106","DOI":"10.14283\/jpad.2024.106"},{"issue":"1","key":"4448_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in Early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"4448_CR37","doi-asserted-by":"publisher","first-page":"n1682","DOI":"10.1136\/bmj.n1682","volume":"374","author":"S Walsh","year":"2021","unstructured":"Walsh S, Merrick R, Milne R, Brayne C (2021) Aducanumab for Alzheimer\u2019s disease? BMJ 374:n1682. https:\/\/doi.org\/10.1136\/bmj.n1682","journal-title":"BMJ"},{"key":"4448_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.med.59.090506.155819","volume":"59","author":"J Woodcock","year":"2008","unstructured":"Woodcock J, Woosley R (2008) The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1\u201312. https:\/\/doi.org\/10.1146\/annurev.med.59.090506.155819","journal-title":"Annu Rev Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04448-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04448-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04448-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:02:14Z","timestamp":1771538534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04448-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4448"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04448-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors confirm that no paper mill and no artificial intelligence was used.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI used"}},{"value":"Not applicable\n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}